DE60313350D1 - Pyrimidin-2,4-dion-derivate als matrix-metalloproteinase-hemmer - Google Patents

Pyrimidin-2,4-dion-derivate als matrix-metalloproteinase-hemmer

Info

Publication number
DE60313350D1
DE60313350D1 DE60313350T DE60313350T DE60313350D1 DE 60313350 D1 DE60313350 D1 DE 60313350D1 DE 60313350 T DE60313350 T DE 60313350T DE 60313350 T DE60313350 T DE 60313350T DE 60313350 D1 DE60313350 D1 DE 60313350D1
Authority
DE
Germany
Prior art keywords
sup
pyrimidin
matrix metalloproteinase
metalloproteinase inhibitors
dion derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60313350T
Other languages
English (en)
Other versions
DE60313350T2 (de
Inventor
James Lester Hicks
William Howard Roark
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Application granted granted Critical
Publication of DE60313350D1 publication Critical patent/DE60313350D1/de
Publication of DE60313350T2 publication Critical patent/DE60313350T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
DE60313350T 2002-08-13 2003-08-04 Pyrimidin-2,4-dion-derivate als matrix-metalloproteinase-hemmer Expired - Fee Related DE60313350T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40302302P 2002-08-13 2002-08-13
US403023P 2002-08-13
PCT/IB2003/003525 WO2004014868A2 (en) 2002-08-13 2003-08-04 Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors

Publications (2)

Publication Number Publication Date
DE60313350D1 true DE60313350D1 (de) 2007-05-31
DE60313350T2 DE60313350T2 (de) 2008-01-03

Family

ID=31715924

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60313350T Expired - Fee Related DE60313350T2 (de) 2002-08-13 2003-08-04 Pyrimidin-2,4-dion-derivate als matrix-metalloproteinase-hemmer

Country Status (11)

Country Link
US (1) US7160893B2 (de)
EP (1) EP1553949B1 (de)
JP (1) JP2006500351A (de)
AT (1) ATE359791T1 (de)
AU (1) AU2003250471A1 (de)
BR (1) BR0313385A (de)
CA (1) CA2497656A1 (de)
DE (1) DE60313350T2 (de)
ES (1) ES2283851T3 (de)
MX (1) MXPA05001783A (de)
WO (1) WO2004014868A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2462442A1 (en) 2001-10-12 2003-04-24 Warner-Lambert Company Llc Alkyne matrix metalloproteinase inhibitors
PA8578101A1 (es) * 2002-08-13 2004-05-07 Warner Lambert Co Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
US20040142950A1 (en) * 2003-01-17 2004-07-22 Bunker Amy Mae Amide and ester matrix metalloproteinase inhibitors
US7183287B2 (en) * 2003-04-03 2007-02-27 Pharmacia Corporation Substituted pyrimidinones
US20070167621A1 (en) 2003-04-03 2007-07-19 Pharmacia Corporation Substituted pyrimidinones
US20060247231A1 (en) * 2003-12-18 2006-11-02 Warner-Lambert Company Llc Amide and ester matrix metalloproteinase inhibitors
NZ549716A (en) * 2004-03-15 2010-04-30 Takeda Pharmaceutical Pyrimidin-dione derivatives as dipeptidyl peptidase inhibitors
EP2708531A1 (de) 2004-10-13 2014-03-19 Pharmacia & Upjohn Company LLC Kristalline Formen Von 3-[5-Chloro-4-[(2,4-difluorbenzyl)oxy]-6-oxopyrimidin-1(6H)-yl]-N-(2-hydroxyethyl)-4-methylbenzamid
KR20070116915A (ko) * 2005-03-24 2007-12-11 얀센 파마슈티카 엔.브이. 프로키네티신 2 수용체 길항제로서의 피리미딘디온 유도체
CL2006003736A1 (es) * 2005-12-29 2008-05-16 Janssen Pharmaceutica Nv Compuestos derivados de triazina o pirimidina sustituida, antagonistas del receptor de prokineticina 1, composicion farmaceutica; y uso en el tratamiento de trastornos gastrointestinales.
CA2635845A1 (en) * 2005-12-29 2007-07-12 Janssen Pharmaceutica N.V. Prokineticin 2 receptor antagonists
TWI394747B (zh) 2006-06-23 2013-05-01 Smithkline Beecham Corp 脯胺醯基羥化酶抑制劑
TW200918507A (en) * 2007-06-29 2009-05-01 Gilead Sciences Inc Novel HIV reverse transcriptase inhibitors
CA2758587A1 (en) * 2009-04-13 2010-10-21 Irm Llc Compositions and methods for modulating retinol binding to retinol binding protein 4 (rbp4)
WO2012006004A1 (en) * 2010-06-28 2012-01-12 Janssen Pharmaceutica Nv Prokineticin 1 receptor antagonists for the treatment of pain
KR20150123917A (ko) * 2013-03-05 2015-11-04 에프. 호프만-라 로슈 아게 항바이러스 화합물
US9199945B2 (en) 2013-06-21 2015-12-01 MyoKardia, Inc. Cycloalkyl-substituted pyrimidinedione compounds
CN105473576B (zh) 2013-06-21 2018-10-30 迈奥卡迪亚公司 针对心脏病症的嘧啶二酮化合物
CN105777653A (zh) * 2014-12-26 2016-07-20 中国科学院上海药物研究所 用作Lp-PLA2抑制剂的嘧啶酮类化合物及其药物组合物
KR101676158B1 (ko) * 2015-03-02 2016-11-23 동국대학교 산학협력단 신규한 6-아미노-5-(치환)피리미딘-2,4(1h,3h)-디온 유도체, 이의 제조방법 및 이의 용도
CN111116492B (zh) * 2019-01-25 2021-07-09 青岛吉澳医药科技有限公司 氘代苯甲氨嘧啶二酮衍生物及其用途

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE284226C (de)
JPS61205261A (ja) * 1985-03-08 1986-09-11 Sagami Chem Res Center ６―置換―５―フルオロウラシル誘導体
DD284226A5 (de) * 1989-06-07 1990-11-07 Akademie Der Wissenschaften Der Ddr,Dd Verfahren zur herstellung von 6-aminosubstituierten 5-methyluracilen
US5425289A (en) 1993-10-21 1995-06-20 Snap-On Incorporated Bung tool
DE3931432A1 (de) 1989-09-21 1991-04-04 Hoechst Ag Pyrimidin-4,6-dicarbonsaeurediamide, verfahren zu deren herstellung sowie verwendung derselben sowie arzneimittel auf basis dieser verbindungen
HU205917B (en) * 1989-09-29 1992-07-28 Mitsubishi Chem Ind Process for producing 6-substituted pyrimidine derivatives and antiviral pharmaceutical compositions containing them as active components
US5260323A (en) 1990-06-28 1993-11-09 Hoechst Aktiengesellschaft 2,4- and 2,5-substituted pyridine-N-oxides, processes for their preparation and their use
EP0541042A1 (de) 1991-11-05 1993-05-12 Hoechst Aktiengesellschaft Pyridin-2,4- und 2,5-dicarbonsäureamide und deren Derivate, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
JP3153387B2 (ja) * 1993-04-28 2001-04-09 富士写真フイルム株式会社 感光材料
US6008243A (en) 1996-10-24 1999-12-28 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use
JPH11199512A (ja) 1997-10-24 1999-07-27 Pfizer Prod Inc 変形性関節症および他のｍｍｐ媒介疾患の治療のためのｍｍｐ−１３選択的阻害剤の使用
NZ507187A (en) * 1998-04-03 2002-10-25 Sankyo Co Aryloxy or heteroaryloxy substituted sulfonamide derivatives useful as matrix metalloproteinase inhibitors
UA59453C2 (uk) 1998-08-12 2003-09-15 Пфайзер Продактс Інк. Похідні гідроксипіпеколат гідроксамової кислоти як інгібітори матричних металопротеїназ
US6177437B1 (en) * 1998-09-04 2001-01-23 University Of Massachusetts Medical Center Inhibitors of Herpes Simplex virus uracil-DNA glycosylase
WO2000051990A1 (en) * 1999-03-04 2000-09-08 Korea Research Institute Of Chemical Technology Antiviral 2,4-pyrimidinedione derivatives and process for the preparation thereof
PA8498701A1 (es) 1999-08-12 2002-08-26 Pfizer Prod Inc Pirimidina-2,4,6-trionas inhibidores de metaloproteinasas
WO2001029010A1 (en) * 1999-10-21 2001-04-26 Merck & Co., Inc. Gram-positive selective antibacterial compounds, compositions containing such compounds and methods of treatment
US6934639B1 (en) 2000-02-25 2005-08-23 Wyeth Methods for designing agents that interact with MMP-13
WO2001072718A1 (fr) * 2000-03-29 2001-10-04 Ishihara Sangyo Kaisha, Ltd. Compositions pharmaceutiques contenant comme ingredient actif des derives de nitropyrimidine ou leurs sels
EP1138680A1 (de) 2000-03-29 2001-10-04 Pfizer Products Inc. Gem substituierte Sulfonylhydroxamsäuren mit MMP inhibierender Wirkung
KR20040004412A (ko) 2000-10-26 2004-01-13 화이자 프로덕츠 인크. 스피로-피리미딘-2,4,6-트리온 메탈로프로테이나제 억제제
PL362919A1 (en) 2000-10-26 2004-11-02 Pfizer Products Inc. Pyrimidine-2,4,6-trione metalloproteinase inhibitors
MXPA03004926A (es) 2001-02-14 2005-02-14 Warner Lambert Co Inhibidores de metaloproteinasas de matriz basados en pirimidinonas fusionadas.
DOP2002000332A (es) 2001-02-14 2002-08-30 Warner Lambert Co Inhibidores de piridina de metaloproteinasas de la matriz
EP1368327B1 (de) 2001-02-14 2004-10-20 Warner-Lambert Company LLC Benzothiadiazine als matrix metallproteinase inhibitoren
PA8539401A1 (es) 2001-02-14 2002-10-28 Warner Lambert Co Quinazolinas como inhibidores de mmp-13
PA8539301A1 (es) 2001-02-14 2002-09-30 Warner Lambert Co Inhibidores de la metaloproteinasa de la matriz
DOP2002000333A (es) 2001-02-14 2002-09-30 Warner Lambert Co Derivados de acido isoftalico como inhibidores de metaloproteinasas de la matriz
PA8539501A1 (es) 2001-02-14 2002-09-30 Warner Lambert Co Compuestos triazolo como inhibidores de mmp
EP1368323B1 (de) 2001-02-14 2010-06-30 Warner-Lambert Company LLC Pyrimidinmatrixmetalloproteinaseinhibitoren
DOP2002000334A (es) 2001-02-14 2002-08-30 Warner Lambert Co Pirimidinas biciclicas como inhibidores de metaloproteinasas de matriz
US6924276B2 (en) 2001-09-10 2005-08-02 Warner-Lambert Company Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
US6962922B2 (en) 2001-10-12 2005-11-08 Warner-Lambert Company Llc Alkynylated quinazoline compounds
CA2462442A1 (en) 2001-10-12 2003-04-24 Warner-Lambert Company Llc Alkyne matrix metalloproteinase inhibitors
WO2003033478A1 (en) 2001-10-12 2003-04-24 Warner-Lambert Company Llc Alkynylated fused ring pyrimidine compounds as matrix metalloprotease-13 inhibitors
US6933298B2 (en) 2001-12-08 2005-08-23 Aventis Pharma Deutschland Gmbh Pyridine-2,4-dicarboxylic acid diamides and pyrimidine-4,6-dicarboxylic acid diamides and the use thereof for selectively inhibiting collagenases
US6894057B2 (en) 2002-03-08 2005-05-17 Warner-Lambert Company Oxo-azabicyclic compounds
US6747147B2 (en) 2002-03-08 2004-06-08 Warner-Lambert Company Oxo-azabicyclic compounds
WO2003076416A1 (en) 2002-03-08 2003-09-18 Warner-Lambert Company Llc Oxo azabicyclic compounds
WO2004000321A1 (en) 2002-06-25 2003-12-31 Warner-Lambert Company Llc Thiazine and oxazine derivatives as mmp-13 inhibitors for treating arthritis
US20040006077A1 (en) 2002-06-25 2004-01-08 Bernard Gaudilliere Thiazine and oxazine derivatives as MMP-13 inhibitors

Also Published As

Publication number Publication date
EP1553949B1 (de) 2007-04-18
WO2004014868A2 (en) 2004-02-19
US20040053952A1 (en) 2004-03-18
AU2003250471A8 (en) 2004-02-25
EP1553949A2 (de) 2005-07-20
WO2004014868A3 (en) 2004-06-03
AU2003250471A1 (en) 2004-02-25
DE60313350T2 (de) 2008-01-03
ATE359791T1 (de) 2007-05-15
ES2283851T3 (es) 2007-11-01
BR0313385A (pt) 2005-06-14
US7160893B2 (en) 2007-01-09
WO2004014868A8 (en) 2004-07-29
JP2006500351A (ja) 2006-01-05
MXPA05001783A (es) 2005-04-25
CA2497656A1 (en) 2004-02-19

Similar Documents

Publication Publication Date Title
DE60313350D1 (de) Pyrimidin-2,4-dion-derivate als matrix-metalloproteinase-hemmer
DE60316013D1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
NO20070557L (no) Ftalazinderivater som PARP-inhibitorer
DE602004008098D1 (de) Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
NO20070555L (no) Kinazolinonderivater som parp-inhibitorer
ATE450533T1 (de) Carboxamidderivate
NO20070526L (no) Kinazolindionderivater som parp-inhibitorer
SE0202463D0 (sv) Novel compounds
ATE394383T1 (de) Biphenylkarbonsäureamidderivate als p38 kinase- inhibitoren
ATE465146T1 (de) 1h-indolderivate als hochselektive cyclooxygenase-2-inhibitoren
ATE553106T1 (de) Heteroarylpyrrolopyridinone als kinaseinhibitoren
ATE302775T1 (de) Carbolinderivate
SE0402762D0 (sv) Indazole sulphonamide derivatives
DK1506185T3 (da) Forbindelser og deres anvendelse som 5-HT-inhibitorer
TR200201205T2 (tr) N-ikame edilmiş karbamoiloksialkil-azolyum türevleri.
TW200508207A (en) New benzimidazole derivatives
ATE374190T1 (de) Tetrahydrochinazolinderivate als cfr-antagonisten
ATE346067T1 (de) Carbolinderivate
SE0101932D0 (sv) Pharmaceutical combinations
GB0308201D0 (en) Novel compounds
EA200301101A1 (ru) Производные пиперазина и их применение в качестве ингибиторов pde4
ATE337320T1 (de) Indolderivate als pde5-inhibitoren
ATE348800T1 (de) 4'-methansulfonylbiphenylderivate als hochselektive cyclooxygenase-2-inhibitoren
ATE246174T1 (de) Tosylprolin-derivate als thymidylat-synthase inhibitoren
DE602004007284D1 (de) Pyrimidine als inhibitoren von phosphoinositid-3-kinasen (pi3k)

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee